Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis-Reference-Cited by-同舟云学术

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

Published:2015-08-25 Issue:4 Volume:62 Page:1037-1046
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kumada Hiromitsu¹,Chayama Kazuaki²,Rodrigues Lino³,Suzuki Fumitaka¹,Ikeda Kenji¹,Toyoda Hidenori⁴,Sato Ken⁵,Karino Yoshiyasu⁶,Matsuzaki Yasushi⁷,Kioka Kiyohide⁸,Setze Carolyn³,Pilot‐Matias Tami³,Patwardhan Meenal³,Vilchez Regis A.³,Burroughs Margaret³,Redman Rebecca³

Affiliation:

1. Department of HepatologyToranomon HospitalTokyo Japan

2. Department of Gastroenterology and Metabolism, Institute of Biomedical and Health SciencesHiroshima UniversityHiroshima Japan

3. AbbVie Inc.North Chicago IL

4. Department of GastroenterologyOgaki Municipal HospitalGifu Japan

5. Department of Medicine and Molecular ScienceGunma University Graduate School of MedicineMaebashi Japan

6. Department of GastroenterologySapporo Kosei General HospitalSapporo Hokkaido Japan

7. Department of Gastroenterology, Tokyo Medical UniversityIbaraki Medical CenterIbaraki Japan

8. Department of Hepatology Osaka City General HospitalOsaka Japan

Funder

Christine Ratajczak (AbbVie)

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27972

Reference35 articles.

1. Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan

2. Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000

3. Distribution of the different subtypes of hepatitis C virus in Japan and the effects of interferon: A nationwide survey

4. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

5. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

2. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance;World Journal of Clinical Cases;2023-08-06

3. Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance;World Journal of Clinical Cases;2023-08-06

4. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

5. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication;Biomedicine & Pharmacotherapy;2022-12